Long Road Investment Counsel LLC Maintains Stake in Core Laboratories (CLB)

Long Road Investment Counsel LLC held its stake in Core Laboratories (NYSE:CLB) during the first quarter, Holdings Channel reports. The fund owned 8,010 shares of the oil and gas company’s stock at the end of the first quarter. Long Road Investment Counsel LLC’s holdings in Core Laboratories were worth $925,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Genesee Valley Trust Co. increased its stake in Core Laboratories by 0.3% in the first quarter. Genesee Valley Trust Co. now owns 5,538 shares of the oil and gas company’s stock worth $639,000 after buying an additional 16 shares during the period. Integrated Investment Consultants LLC increased its stake in Core Laboratories by 0.8% in the first quarter. Integrated Investment Consultants LLC now owns 2,330 shares of the oil and gas company’s stock worth $269,000 after buying an additional 19 shares during the period. Cetera Advisors LLC increased its stake in Core Laboratories by 0.7% in the third quarter. Cetera Advisors LLC now owns 3,611 shares of the oil and gas company’s stock worth $398,000 after buying an additional 24 shares during the period. Creative Planning increased its stake in Core Laboratories by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock worth $200,000 after buying an additional 33 shares during the period. Finally, First Bank & Trust increased its stake in Core Laboratories by 2.7% in the first quarter. First Bank & Trust now owns 1,411 shares of the oil and gas company’s stock worth $163,000 after buying an additional 37 shares during the period.

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Core Laboratories (NYSE:CLB) traded up 2.73% during mid-day trading on Friday, hitting $108.67. The stock had a trading volume of 455,265 shares. Core Laboratories has a 1-year low of $96.30 and a 1-year high of $133.38. The company has a market cap of $4.80 billion, a P/E ratio of 71.97 and a beta of 1.55. The company has a 50-day moving average price of $111.82 and a 200 day moving average price of $113.71.

Core Laboratories (NYSE:CLB) last released its earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.03. Core Laboratories had a net margin of 10.74% and a return on equity of 65.65%. The firm had revenue of $157.81 million during the quarter, compared to analyst estimates of $150.44 million. During the same quarter in the previous year, the business earned $0.37 EPS. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Equities research analysts forecast that Core Laboratories will post $2.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 23rd. Stockholders of record on Friday, April 28th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, April 27th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.08%. Core Laboratories’s dividend payout ratio is 150.68%.

TRADEMARK VIOLATION NOTICE: “Long Road Investment Counsel LLC Maintains Stake in Core Laboratories (CLB)” was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.mideasttime.com/long-road-investment-counsel-llc-maintains-stake-in-core-laboratories-clb/1709032.html.

A number of brokerages have recently commented on CLB. Scotiabank set a $136.00 price objective on Core Laboratories and gave the company a “hold” rating in a research report on Saturday, April 22nd. Tudor Pickering began coverage on Core Laboratories in a research report on Thursday, March 23rd. They set a “hold” rating for the company. Zacks Investment Research downgraded Core Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, April 11th. ABN Amro upgraded Core Laboratories to a “hold” rating in a research report on Friday, April 21st. Finally, Citigroup Inc reiterated a “neutral” rating and set a $117.00 price objective (down previously from $119.00) on shares of Core Laboratories in a research report on Saturday, March 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $125.60.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

12 Month Chart for NYSE:CLB

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.